Brief: TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity Of Co's Novel TRuC-T Cells
07/05/2019 10:18
May 7 (Reuters) - Tcr2 Therapeutics Inc TCRR.O :
* TCR2 THERAPEUTICS PUBLISHES FIRST PEER-REVIEWED DATA
DEMONSTRATING SUPERIOR ANTI-TUMOR ACTIVITY OF THE COMPANY’S
NOVEL TRUC™-T CELLS
Source text for Eikon: ID:nGNX3R5bxZ
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview